undamentalytics Newsletter
Sign in

Volitionrx LTD (VNRX) stock

Add to watchlist

Add holding +

NYSE: VNRX NYSE Health Care Equipment Next results ~November 12, 2026

D Fundamentals grade

Volitionrx LTD is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.2

Price-to-sales vs peers

Base case. Range ~$0.2–$1.0. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Volitionrx LTD valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds25 adding, 0 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Volitionrx files

Where Volitionrx LTD stands after its latest 10-Q

Volitionrx LTD has little or no product revenue yet; it used $20m of cash in the twelve months to June 2026. That growth ranks 5 of 103 among the health care equipment companies we cover. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 0 of our 4 financial-health checks. Our price-to-sales vs peers value is $0.26 a share.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Volitionrx LTD's trailing-twelve-month revenue grew 86.3% year on year, with a free-cash-flow margin of -796.7%. Where it stands out: revenue growth of 86.3% ranks 6 of 129 health care equipment companies we cover. Where it lags: long-term debt as % of assets of 72.1% ranks 84 of 87 health care equipment companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 9.6% while net income fell 9.9%: a 20pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 86.3% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Margins widening. Operating margin is up 988.8 points on a year ago.

Things to watch

  • Results due soon. Results are expected around 12 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -790.2%: costs exceed revenue.
  • Burning cash. Free cash flow was -796.7% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 38.2% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 16.3% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 109% and a beta of 1.0 against the S&P 500.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$0.59 against an average estimate of -$0.67: beat by 12.7%
Revenue
$0m, down 2.0% on a year earlier
Share reaction
-19.4% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.31

Volitionrx's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+5.0%
  • 1 week+16.7%
  • 1 month-12.5%
  • This year-96.0%
  • 1 year-97.6%
  • 5 years-99.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$2.5M
Operating margin
-790.2%
Net margin
-1043.1%
EPS (TTM, diluted)
$-5.12

Growth

Revenue growth
+86.3%
Change in growth rate
−2.2 pts

Cash

Free cash flow (TTM)
-$19.6M
FCF margin
-796.7%
Stock pay % of revenue
38.2%

Earnings

Last results
August 13, 2026
Next results (est.)
November 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Share issue
  3. Share issue
  4. Announcement
  5. Agreement
  6. Share issue
  7. Share issue
  8. Results
  9. Share issue
  10. Shareholder vote

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Volitionrx LTD valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Volitionrx LTD as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.02 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: book value or earnings not available
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.2 ~$0.2–$1.0 Included, half weight
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.2 ~$0.2–$1.0 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Volitionrx LTD with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 201920202021202320242025
Share price$94.80$77.80$62.80$14.40$12.00$5.20
Market value$3.7bn$3.5bn$3.3bn$1.0bn$1.0bn$556m
+ Net debt (− = net cash)−$14m−$16m−$18m−$16m$2m$7m
Enterprise value$3.7bn$3.5bn$3.3bn$1.0bn$1.0bn$563m
Multiples
Price / sales n/mn/mn/mn/mn/mn/m
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

12 /100

Weak moat

How hard Volitionrx's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -113.7% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -7050.0%; its worst year was -83145.3%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 8 years, at a median -5092.3% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 279.9% over five years; stock-based pay has been a median 336.8% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, after the close. Analysts expect revenue of $696150 and EPS of −$0.31 (range −$0.31 to −$0.31) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.00 +55% $3m +58%
Next −$0.85 +58% $9m +241%

Next year's EPS estimate has moved −107.9% in 90 days, across 1 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −23.1% on 90 days ago. In the last 30 days, 1 analyst raised Volitionrx LTD's forecast and 0 cut it.

Consensus EPS forecast Volitionrx LTD, last 90 days
−$5.00 $0.00 $5.00 $10.00 $15.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.60 Current fiscal year, 60 days ago: −$2.62 Current fiscal year, 30 days ago: −$2.62 Current fiscal year, 7 days ago: −$2.62 Current fiscal year, Now: −$2.00 −$2.00 Next fiscal year, 90 days ago: $10.80 Next fiscal year, 60 days ago: −$1.15 Next fiscal year, 30 days ago: −$1.15 Next fiscal year, 7 days ago: −$1.15 Next fiscal year, Now: −$0.85 −$0.85

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.60$10.80
60 days ago −$2.62−$1.15
30 days ago −$2.62−$1.15
7 days ago −$2.62−$1.15
Now −$2.00−$0.85

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.67 −$0.59 +12.7%
Mar 2026 −$0.73 −$0.84 −14.2%
Dec 2025 −$0.80 −$0.91 −13.5%
Sept 2025 −$1.04 −$1.06 −1.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Oct 2026
Buy480%
Hold120%
Sell00%

Monthly trend

  1. Oct 20261315
  2. Sep 20261315
  3. Aug 20261315

Counts of recommendations published by analysts covering Volitionrx LTD, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.9%
of tradable shares
Days to cover
0.38
at average volume
Short interest, 1 month
+14%
to October 15, 2026
Held by institutions
11%
of shares
Held by insiders
3.3%
of shares
Employees
57
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months −97.6%

$8.60 on October 31, 2025 to $0.21

ThenNowEffect
Revenue (last 12 months) $1m $2m +86.3%
P/S multiple 31.0x 0.6x −98.2%
Share count 5m 7m −28.4%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
VNRX−19%−23%−70%−17%−57%−96%
Industry peers (median)−7%−37%−8%−20%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
VNRX33%42%17%42%33%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
VNRX−54%−58%−80%−58%−74%−98%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 100% from February 8, 2021 to October 19, 2026. Getting back needed a 76371% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.17 – $9.00
From 52-week high
−97.7%
vs 50-day average
−20.9%
vs 200-day average
−90.2%
Volatility (1 year)
109%
Beta vs S&P 500
1.04

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±9.0%
After a week
6 up, 6 down
typical move ±12.8%
After a month
4 up, 8 down
typical move ±26.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −19.4% +0.5% −34.3% −53.7%
May 14, 2026 −15.3% −0.4% +14.4% −39.0%
March 31, 2026 +5.3% +3.7% −10.5% −31.1%
November 13, 2025 −10.8% −1.7% −10.8% −35.1%
October 14, 2025 −2.2% +0.3% −4.4% −17.8%
August 14, 2025 +11.3% −0.2% +9.7% +1.6%
May 15, 2025 −8.5% +1.1% +10.6% +53.2%
March 31, 2025 −5.5% +1.0% −9.1% −12.7%
November 14, 2024 −10.5% −1.9% +6.6% −18.4%
August 14, 2024 +7.5% +2.0% +28.3% +28.3%
May 13, 2024 −9.6% +0.5% −9.6% −16.9%
March 25, 2024 +2.7% −0.5% +5.5% +9.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Volitionrx LTD in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Volitionrx LTD
$0 $1M $2M $3M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $651K Revenue (TTM), FY23 Q4: $775.3K Revenue (TTM), FY24 Q1: $797K Revenue (TTM), FY24 Q2: $976.5K Revenue (TTM), FY24 Q3: $1.3M Revenue (TTM), FY24 Q4: $1.2M Revenue (TTM), FY25 Q1: $1.3M Revenue (TTM), FY25 Q2: $1.3M Revenue (TTM), FY25 Q3: $1.5M Revenue (TTM), FY25 Q4: $1.7M Revenue (TTM), FY26 Q1: $2.5M Revenue (TTM), FY26 Q2: $2.5M $2.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $651K
FY23 Q4 $775.3K
FY24 Q1 $797K
FY24 Q2 $976.5K
FY24 Q3 $1.3M
FY24 Q4 $1.2M
FY25 Q1 $1.3M
FY25 Q2 $1.3M
FY25 Q3 $1.5M
FY25 Q4 $1.7M
FY26 Q1 $2.5M
FY26 Q2 $2.5M
Revenue growth, TTM YoY Volitionrx LTD
0% 100% 200% 300% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 224.0% Revenue growth, TTM YoY, FY23 Q4: 153.0% Revenue growth, TTM YoY, FY24 Q1: 133.1% Revenue growth, TTM YoY, FY24 Q2: 88.3% Revenue growth, TTM YoY, FY24 Q3: 97.5% Revenue growth, TTM YoY, FY24 Q4: 59.1% Revenue growth, TTM YoY, FY25 Q1: 64.2% Revenue growth, TTM YoY, FY25 Q2: 35.1% Revenue growth, TTM YoY, FY25 Q3: 14.5% Revenue growth, TTM YoY, FY25 Q4: 40.0% Revenue growth, TTM YoY, FY26 Q1: 88.5% Revenue growth, TTM YoY, FY26 Q2: 86.3% 86.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 224.0%
FY23 Q4 153.0%
FY24 Q1 133.1%
FY24 Q2 88.3%
FY24 Q3 97.5%
FY24 Q4 59.1%
FY25 Q1 64.2%
FY25 Q2 35.1%
FY25 Q3 14.5%
FY25 Q4 40.0%
FY26 Q1 88.5%
FY26 Q2 86.3%
Operating margin (TTM) Volitionrx LTD
-6000% -4000% -2000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -5415.6% Operating margin (TTM), FY23 Q4: -4641.8% Operating margin (TTM), FY24 Q1: -4432.4% Operating margin (TTM), FY24 Q2: -3355.7% Operating margin (TTM), FY24 Q3: -2331.9% Operating margin (TTM), FY24 Q4: -2190.9% Operating margin (TTM), FY25 Q1: -1846.8% Operating margin (TTM), FY25 Q2: -1779.0% Operating margin (TTM), FY25 Q3: -1542.2% Operating margin (TTM), FY25 Q4: -1258.5% Operating margin (TTM), FY26 Q1: -874.5% Operating margin (TTM), FY26 Q2: -790.2% -790.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -5415.6%
FY23 Q4 -4641.8%
FY24 Q1 -4432.4%
FY24 Q2 -3355.7%
FY24 Q3 -2331.9%
FY24 Q4 -2190.9%
FY25 Q1 -1846.8%
FY25 Q2 -1779.0%
FY25 Q3 -1542.2%
FY25 Q4 -1258.5%
FY26 Q1 -874.5%
FY26 Q2 -790.2%
FCF margin (TTM) Volitionrx LTD
-6000% -4000% -2000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -4864.2% FCF margin (TTM), FY23 Q4: -2469.6% FCF margin (TTM), FY24 Q1: -2330.2% FCF margin (TTM), FY24 Q2: -1812.1% FCF margin (TTM), FY24 Q3: -1129.8% FCF margin (TTM), FY24 Q4: -2121.7% FCF margin (TTM), FY25 Q1: -1689.1% FCF margin (TTM), FY25 Q2: -1642.4% FCF margin (TTM), FY25 Q3: -1343.4% FCF margin (TTM), FY25 Q4: -1144.7% FCF margin (TTM), FY26 Q1: -841.9% FCF margin (TTM), FY26 Q2: -796.7% -796.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -4864.2%
FY23 Q4 -2469.6%
FY24 Q1 -2330.2%
FY24 Q2 -1812.1%
FY24 Q3 -1129.8%
FY24 Q4 -2121.7%
FY25 Q1 -1689.1%
FY25 Q2 -1642.4%
FY25 Q3 -1343.4%
FY25 Q4 -1144.7%
FY26 Q1 -841.9%
FY26 Q2 -796.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-KT/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Dec 2011 2012 Dec 2012 2014 Dec 2014 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 0 0 0 0 0 1 1 2 2
EBITDA −2 −4 −6 −15 −21 −27 −31 −35 −26 −21 −19
Operating income −3 −4 −6 −16 −21 −28 −32 −36 −27 −22 −19
Net income −3 −4 −8 −16 −20 −27 −31 −36 −27 −23 −26
Diluted EPS −$0.15 −$0.15 −$0.20 −$0.41 −$0.45 −$0.51 — −$0.50 −$0.31 — —
Growth (year on year)
Revenue — — −73.1% +15.6% −21.4% +570.3% +240.3% +153.0% +59.1% +40.0% +86.3%
Margins
EBITDA margin — <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% −754.7%
Operating margin — <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% −790.2%
Net margin — <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999%
Free-cash-flow margin — <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% <−999% −796.7%
Cash flow
Cash from operations −2 −2 −4 −13 −16 −21 −15 −18 −26 −20 −20
Capital spending 0 0 0 1 2 1 2 1 0 0 0
Free cash flow −2 −2 −4 −13 −18 −22 −17 −19 −26 −20 −20
Stock-based pay 0 1 1 1 1 2 3 2 1 2 1
Free cash flow after stock pay −2 −3 −5 −15 −20 −24 −20 −21 −27 −22 −21
Balance sheet
Cash 0 0 2 17 19 21 11 21 3 1 3
Total debt 0 0 0 3 3 3 4 5 5 8 9
Net debt (negative = net cash) −0 −0 −2 −14 −16 −18 −7 −16 2 7 7
Diluted shares — 28m 40m 39m 45m 53m — 71m 87m 107m —
Returned to shareholders
Buybacks — — — — — — 0 0 0 — —
Total returned — — — — — — 0 0 0 — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

0 of 4 checks passed · June 30, 2026
What it owns · $8m
Short-term assets $4mLonger-term assets $4m
What it owes, and who funded it · $42m
Short-term liabilities $13mLonger-term liabilities $28mShareholders' equity $-32m
  • Short-term assets cover short-term liabilities $4m of assets due within a year against $13m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $4m short-term assets against $28m of longer-dated liabilities.
  • More cash than debt $3m of cash against $7m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$20m of operating cash flow against $7m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Volitionrx LTD's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
382.7%
of revenue
Days sales outstanding
41 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated VNRX FEMY ICCM ICU IMDX CNSY Median
Revenue, last 12 months $2m $2m $3m $2m $2m $4m $99m
Revenue growth, last 12 months 86.3% 21.9% 2.7% 123.6% −60.8% −21.0% 9.2%
Revenue growth, 3-year average 68.0% 24.3% — — 14.9% 16.1% 13.5%
Revenue growth, latest quarter −2.0% −18.9% — 82.0% −53.9% −70.4% 10.2%
Gross margin — 60.9% 36.3% 92.6% 48.3% 15.1% 61.2%
Operating margin −790.2% −763.9% −446.7% −816.6% <−999% −628.1% −8.5%
Operating margin, 3-year average <−999% <−999% — — <−999% −383.3% −17.9%
Net margin <−999% −511.8% −445.6% −795.5% <−999% −620.7% −12.0%
Cash from operations / revenue −795.9% −767.6% −431.3% −799.4% <−999% −527.6% −1.9%
Free-cash-flow margin −796.7% −786.0% −432.4% — <−999% −560.3% −3.9%
Free-cash-flow margin, 3-year average <−999% <−999% — — <−999% −402.6% −7.0%
Stock pay / revenue 38.2% 26.2% 40.6% 20.5% 150.8% 73.6% 6.1%
Change in share count 16.3% — 25.0% — 16.8% −99.4% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 86.3% 9.1% 6 of 129
Change in growth rate Growth -2.2pp -0.6pp 85 of 129
Operating margin Profitability -790.2% -8.3% 119 of 132
Net margin Profitability -1043.1% -12.0% 123 of 133
Free-cash-flow margin Cash generation -796.7% -3.4% 119 of 128
Stock pay as % of revenue Cash generation 38.2% 6.1% 108 of 123
Long-term debt as % of assets Balance sheet 72.1% 24.2% 84 of 87
Days sales outstanding Balance sheet 41 days 57 days 20 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$2.6M
Institutions reporting
25
Positions opened / closed
25 / 0

Top buyers and sellers, Q2 2026: 25 institutions bought and 0 sold ; the biggest buyer was Lagoda Investment Management, L.P (+1.5M shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Lagoda Investment Management, L.P. $2M 1.5M 75.4% —
Luminus Management LLC $211,811 157K 8.1% —
Geode Capital Management, LLC $74,986 56K 2.9% —
Vanguard Capital Management LLC $68,423 51K 2.6% —
Wealthspire Advisors, LLC $60,750 45K 2.3% —
State Street Corp $45,893 34K 1.8% —
Xtx Topco Ltd $34,264 25K 1.3% —
Vanguard Fiduciary Trust Co $33,930 25K 1.3% —
Blackrock, Inc. $30,116 22K 1.2% —
Northern Trust Corp $17,520 13K 0.7% —
Silverberg Bernstein Capital Management LLC $16,902 13K 0.6% —
Squarepoint Ops LLC $14,425 11K 0.6% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Volitionrx LTD's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $7,000 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $7,000 net buying
Insider Date Trade Shares Price Value
Reynolds Cameron John President and CEO November 17, 2025 Buy 20,000 $0.35 $7,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 14, 2026
  • March 31, 2026
  • November 13, 2025
  • October 14, 2025
  • August 14, 2025

Recent SEC filings

Data status

When each part of this page on Volitionrx LTD was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Volitionrx LTD in brief

What does Volitionrx LTD do?
Volitionrx LTD is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Volitionrx LTD's stock ticker?
Volitionrx LTD trades under the ticker VNRX on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Volitionrx LTD's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Volitionrx LTD reported revenue of $2.5M, 86.3% higher than a year earlier, according to its SEC filings.
What is Volitionrx LTD's free cash flow?
Volitionrx LTD's free-cash-flow margin is -796.7% of revenue over the trailing twelve months, ranking 119 of the 128 health care equipment companies we cover.
Who are Volitionrx LTD's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Lagoda Investment Management, L.P., Luminus Management LLC and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Volitionrx LTD's market cap?
On December 31, 2025, Volitionrx LTD's market capitalisation was about $556M and net debt of $7.1M. Market figures come from third-party market data and may be delayed.
Who are Volitionrx LTD's competitors?
In our Health Care Equipment peer group, the companies closest to Volitionrx LTD are Femasys Inc, Icecure Medical Ltd., Seastar Medical Holding Corp, Insight Molecular Diagnostics Inc. and Cerenome, Inc. The side-by-side comparison below sets their revenue, margins and growth against Volitionrx LTD's.
Are insiders buying or selling Volitionrx LTD stock?
Over the last 12 months, Volitionrx LTD's directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Volitionrx LTD's next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Volitionrx LTD announces its own schedule.